GLP-1 drugs show cardiovascular benefits in diabetes trials and may help cancer patients who face elevated heart disease risk from their treatments.
Multi-pathway cardioprotectionGLP-1 drugs act through cAMP, PI3K/AKT, and anti-inflammatory pathways to reduce cardiovascular risk
What the researchers found
Cancer patients face elevated cardiovascular risk from both the cancer itself and cardiotoxic treatments. GLP-1 receptor agonists have shown multiple cardiovascular benefits in large diabetes trials: reduced atherosclerosis, heart failure prevention, and kidney protection.
The mechanisms involve activation of cAMP and PI3K/AKT pathways (which promote cell survival) and inhibition of NLRP-3 inflammasome and MyD88 (which drive inflammation). These same pathways are involved in chemotherapy-induced cardiac damage, suggesting GLP-1 drugs could offer cardioprotection during cancer treatment.
The review highlights that no dedicated trial has tested GLP-1 drugs specifically for cardiac protection in cancer patients.
Why it matters
Cardio-oncology is a growing field because more cancer patients survive long enough to develop heart disease from their treatments. Many cancer patients also have type 2 diabetes, making them candidates for GLP-1 therapy. If GLP-1 drugs can protect the heart during and after cancer treatment, they could address two problems at once.
The numbers in context
- GLP-1 drugs activate cAMP and PI3K/AKT pathways
- GLP-1 drugs inhibit NLRP-3 and MyD88 inflammatory pathways
- Cardiovascular outcome trials show heart failure and atherosclerosis prevention
- No dedicated cancer-patient cardiac protection trial exists
How the study worked
Narrative review analyzing clinical evidence from cardiovascular outcome trials of GLP-1 drugs and preclinical evidence of their mechanisms in cardiac protection. The authors examined how these mechanisms might apply to cancer-related cardiovascular disease.
Who was studied
Review focused on cancer patients with type 2 diabetes at risk for cardiovascular complications
What this study cannot tell us
This is a narrative review with no original data. The cardiovascular outcome trials that showed GLP-1 benefits excluded most cancer patients. The proposed mechanisms are based on preclinical data and extrapolation from diabetes trials. No clinical trial has tested GLP-1 drugs specifically for cardioprotection in cancer patients. The review does not address potential interactions between GLP-1 drugs and cancer treatments.
How to read the evidence
Rated preliminary: extrapolates cardiovascular benefits from diabetes trials to cancer patients, a population not studied directly.
When this study was published
Published in 2024. No dedicated GLP-1 trials in cancer survivors have been conducted yet.
The bigger picture
Cardio-oncology is growing because more cancer patients survive long enough to develop treatment-related heart disease. GLP-1 drugs could serve double duty for the many cancer survivors who also have type 2 diabetes.
Questions still open
- Would a clinical trial of GLP-1 drugs specifically in cancer survivors show cardiovascular benefit?
- Could GLP-1 drugs interfere with cancer treatments?
Common questions
Can GLP-1 drugs help cancer patients?
What heart risks do cancer survivors face?
Read the original research
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.
International journal of molecular sciences, 25(20)
Citation
Quagliariello, Vincenzo; Canale, Maria Laura; Bisceglia, Irma; Iovine, Martina; Giordano, Vienna; Giacobbe, Ilaria; Scherillo, Marino; Gabrielli, Domenico; Maurea, Carlo; Barbato, Matteo; Inno, Alessandro; Berretta, Massimiliano; Tedeschi, Andrea; Oliva, Stefano; Greco, Alessandra; Maurea, Nicola. (2024). Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.. International journal of molecular sciences, 25(20). https://doi.org/10.3390/ijms252011299